Pharm-BioTechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science & Technology, P. O. Box, 1410, Mbarara, Uganda; School of Nursing and Midwifery, College of Medicine and Health Sciences, University of Rwanda, University Avenue, P.O. Box 56, Butare, Rwanda.
Pharm-BioTechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science & Technology, P. O. Box, 1410, Mbarara, Uganda; Faculity of Medicine, College of Medicine and Health Sciences, Hawassa University, P. O. Box 1560 Hawassa, Ethiopia.
Tuberculosis (Edinb). 2020 Sep;124:101987. doi: 10.1016/j.tube.2020.101987. Epub 2020 Aug 16.
Regimens of current drugs for tuberculosis are lengthy and are associated with many adverse effects. Currently, the emergence of different resistant strains has been observed. This urges a need for the discovery and development of novel drugs. The main sources of drug lead candidates are based on natural products. Zanthoxylum leprieurii, Lantana camara, and Cryptolepis Sanguinolenta are among the plants that have antimycobacterial activity. Recent technological methods, such as metabolomics, can rapidly detect and identify active compounds from medicinal plants. In this review, we aim to provide an overview and discussion of the antimycobacterial activity, phytochemical analysis and toxicity profile of these plants and their products as well as the potential of metabolomic fingerprinting of medicinal plants with a given activity on microbes, in the search for the potential drug hit molecules. The information for this review was extracted from databases such as Excerpta Medica Database, Google Scholar, Springer, and PubMed Central. Primary studies, using a combination of the keywords antimycobacterial medicinal plant, multidrug-resistant tuberculosis, phytochemistry, toxicity, Zanthoxylum leprieurii, Lantana camara, Cryptolepis sanguinolenta, and plant metabolomics/metabolic fingerprinting of plant extracts, have been considered. The above-mentioned plant species showed antimycobacterial activity against drug-resistant strains of M. tuberculosis. They may provide potential candidates for novel drugs against multidrug-resistant tuberculosis. However, extensive work is still needed. To our knowledge, there is no or limited literature that reports the metabolic fingerprints of these plants. The analysis of the metabolite fingerprints of medicinal plants with similar antimicrobial activity could be important to determine whether the activity results from common metabolites within different plant species. This review shows that these plants are potential candidates to provide drug hits against multidrug-resistant tuberculosis strains. Future studies of compound optimization, in vivo safety and efficacy, as well as of the specific mechanisms of action are however required.
当前治疗结核病的药物方案疗程长，且副作用多。目前，不同耐药菌株的出现已经引起关注。因此，需要开发新的药物。药物先导候选物的主要来源基于天然产物。花椒、黄荆和千里光等植物具有抗分枝杆菌活性。最近的技术方法，如代谢组学，可以快速从药用植物中检测和鉴定活性化合物。在本综述中，我们旨在概述和讨论这些植物及其产物的抗分枝杆菌活性、植物化学分析和毒性概况，以及具有特定微生物活性的药用植物代谢组学指纹图谱的潜力，以寻找潜在的药物命中分子。本综述的信息来自 Excerpta Medica Database、Google Scholar、Springer 和 PubMed Central 等数据库。主要研究采用了组合关键词，如抗分枝杆菌药用植物、耐多药结核病、植物化学、毒性、花椒、黄荆、千里光和植物代谢组学/植物提取物的代谢指纹图谱。上述植物种类对耐多药结核分枝杆菌菌株具有抗分枝杆菌活性。它们可能为治疗耐多药结核病的新型药物提供潜在候选物。然而，仍需要广泛的研究。据我们所知，没有或有限的文献报道这些植物的代谢指纹图谱。分析具有相似抗菌活性的药用植物的代谢指纹图谱对于确定活性是否来自不同植物物种中的常见代谢物可能很重要。本综述表明，这些植物是针对耐多药结核分枝杆菌菌株提供药物命中的潜在候选物。然而，需要进一步研究化合物优化、体内安全性和疗效以及具体作用机制。
